Since the discovery of the penicillin in 1928, large amount of antibiotics are used for human therapy, as well as for farm animals and even for fish in aquaculture, resulted in the selection of pathogenic bacteria resistant to multiple drugs. This multidrug-resistant may be generated by two mechanisms. One is bacteria may accumulate multiple genes, each coding for resistant to the single drug, within a single cell. Another mechanism is increased gene expressions that code for multidrug efflux pumps, effects a wide range of drugs. Multi drug resistant bacteria are formed due to the excessive use of antibiotics in various applications such as prophylactic use for surgery, or immunocompromised patients and other applications. Multi drug resistant antibiotics are the new generation antibiotics that fight against the drug resistant bacteria.
Some of the players in Multi-Drug Resistant Antibiotics Market are:
F. Hoffmann-La Roche AG (Switzerland), Achaogen Inc. (U.S.), Acetlion Pharmaceuticals (Switzerland), Sanofi S.A (France), Johnson & Johnson Servieces Inc. (U.S.), Pfizer Inc. (U.S.), Otsuka Pharmaceutical (Japan), and Eli Lilly and Company (U.S.) to name a few.
No comments:
Post a Comment